

Curriculum Vitae

Personal information **Charlotta Bergquist**

Work experience

1. Employer: Medical Products Agency
 - Start date: 052006
 - End date:
 - Position: Group manager, clinical assessor
 - Activities: Main responsibilities: Assessing the clinical part of Marketing authorization applications for vaccines, national and EU Applications, and other regulatory procedures for vaccines (e.g. variations, Follow-up measures). Member of the CHMP Vaccine Working Party since 2014. Goup leader of Clinical Group 2 (infectious disease Group) at the MPA since January 1, 2018.
 - Country: Sweden
2. Employer: SBL Vaccines
 - Start date: 082005
 - End date: 042006
 - Position: Head of Research Immunology and Microbiology
 - Activities:
 - Country: Sweden
3. Employer: SBL Vaccines
 - Start date: 092000
 - End date: 072005
 - Position: Medical Affairs manager
 - Activities:
 - Country: Sweden
4. Employer: Göteborg University
 - Start date: 011998
 - End date: 031999
 - Position: post_doc position
 - Activities: Research in the area of mucosal vaccinations
 - Country: Sweden

Education and training

1. Subject: Göteborg university, , Department of Medical Microbiology and Immunology
 - Start date: 011993
 - End date: 121997
 - Qualification: PhD
 - Organisation: Title of Thesis: Development of Nasal vaccines based on cholera toxin B subunit conjugated to bacterial polysaccharides.
 - Country: Sweden
2. Subject: Lund University
 - Start date: 011987
 - End date: 061990
 - Qualification: MSc, Biology
 - Organisation:
 - Country: Sweden

Additional information

Publications

Antivirala medel för det initiala skedet _ vaccine begränsar effekterna på sikt. Den nya pandemiinfluansan A/H1N1. Uhnöo I, Bergquist C. Läkartidningen. 2009. 106 (28_29); 1814_1819. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Johansson EL, Bergquist C, Edebo A, Johansson C, Svennerholm AM. Vaccine. 2004 Feb 25;22(8):984_90. Oral B subunit_killed whole_cell cholera vaccine. Holmgren J, Bergquist, C. In New Generation Vaccines, 3rd ed. Marcel Dekker Inc. Ed: Levine, M.M., Kaper, J. B., Rappuoli, R. Liu, M. A., Good, M. F. 2004. 499_509. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection. Larsson C, Holmgren J, Lindahl G, Bergquist C. Infect Immun. 2004 Feb;72(2):1184_7. Development of a new method for the determination of immune responses in the human stomach. Bergquist C, Mattsson_Rydberg A, Lönnroth H, Svennerholm A. J Immunol Methods. 2000 Feb 3;234(1_2):51_9. Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid. Bergquist C, Lagergård T, Holmgren J. APMIS. 1998 Aug;106(8):800_6. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Rudin A, Johansson EL, Bergquist C, Holmgren J. Infect Immun. 1998 Jul;66(7):3390_6. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Bergquist C, Johansson EL, Lagergård T, Holmgren J, Rudin A. Infect Immun. 1997 Jul;65(7):2676_84. Anticardiac immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide_protein conjugate. Bergquist C, Lagergård T, Holmgren J. Infect Immun. 1997 May;65(5):1579_83. Local and systemic antibody responses to dextran_cholera toxin B subunit conjugates. Bergquist C, Lagergård T, Lindblad M, Holmgren J. Infect Immun. 1995 May;63(5):2021_5. Structure_activity relationships for unsaturated dialdehydes. VIII: Comparative effects of 10 sesquiterpenoids on the sea urchin gamete fertilization. Bergquist J. ; Strandberg C; Andersson M; Sterner O; Pesando D ; Girard J._P ; Toxicology in vitro 1993, vol. 7, no3, pp. 205_212

Projects

Memberships

Other Relevant Information